 Indoles
"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 | | 1997 | 3 | 4 | 7 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 3 | 4 | | 2001 | 2 | 3 | 5 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 3 | 3 | | 2004 | 1 | 5 | 6 | | 2005 | 1 | 3 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 5 | 7 | 12 | | 2008 | 3 | 4 | 7 | | 2009 | 3 | 7 | 10 | | 2010 | 1 | 2 | 3 | | 2011 | 3 | 7 | 10 | | 2012 | 6 | 12 | 18 | | 2013 | 8 | 10 | 18 | | 2014 | 12 | 9 | 21 | | 2015 | 11 | 10 | 21 | | 2016 | 7 | 2 | 9 | | 2017 | 9 | 7 | 16 | | 2018 | 8 | 4 | 12 | | 2019 | 6 | 10 | 16 | | 2020 | 2 | 6 | 8 | | 2021 | 8 | 7 | 15 | | 2022 | 0 | 10 | 10 | | 2023 | 2 | 13 | 15 | | 2024 | 12 | 12 | 24 | | 2025 | 16 | 7 | 23 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM. Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Ann Am Thorac Soc. 2026 Feb 01; 23(2):241-251.
-
Liu CM, Fischer JL, Overdevest JB, Zemke AC, Strand MJ, Gudis DA, Kimple AJ, Tervo JP, DiMango E, Goralski JL, Keating C, Senior B, Stapleton AL, Taylor-Cousar JL, Beswick DM. Psychometric validity of the 22-item sinonasal outcome test in cystic fibrosis. J Cyst Fibros. 2026 Mar; 25(2):353-358.
-
Mandala A, Undi RB, Janssen RC, Sugino KY, Zhao W, Nelson BN, Teague AM, Patil NY, Zemsky Berry K, Varshney R, Bergman BC, Rudolph MC, Joshi AD, Rajala RVS, Jonscher KR, Friedman JE. Reprogramming offspring liver health: maternal indole supplementation as a preventive strategy against MASLD. EBioMedicine. 2026 Jan; 123:106098.
-
Lyons ER, Vigers T, Simoni M, Lynn C, Muther E. Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis. Pediatr Pulmonol. 2025 Dec; 60(12):e71418.
-
Ye W, Magee JC, Huang S, Leung DH, Bozic M, Stoll J, C Ling S, Paranjape SM, Karnsakul W, Jay Freeman A, Schwarzenberg SJ, Palermo J, Alonso E, Green N, Masand P, Karmazyn B, Harned R, Navarro OM, Siegel MJ, Towbin A, Alazraki A, Otto RK, Nicholas JL, Narkewicz MR. Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Knoll RL, Brauny MM, Robert E, Cloos L, Waser L, Hilbert K, Ulmer N, Hillen B, Birkner T, Bartolomaeus TUP, Nitsche O, Jarquín-Díaz VH, Lynch S, Gehring S, Maier L, Poplawska K, Forslund-Startceva SK. CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial. Nat Commun. 2025 Nov 18; 16(1):10111.
-
Vladar EK, Gillen AE, Yadav S, Murphree MR, Baraghoshi D, Harris JK, Pruesse E, Niemiec SS, Wilson AW, Hisert KB, Humphries SM, Strand M, Lynch DA, Seibold MA, Beswick DM, Taylor-Cousar JL. Transcriptomic and functional responses of the cystic fibrosis airway epithelium to CFTR modulator therapy. JCI Insight. 2025 Nov 10; 10(21).
-
Pittman JE, Morgan S, McCreary M, Vu PT, Jorth P, Heltshe S, Hoffman LR, Kelly A, Sagel SD, Singh PK, Solomon GM, Rosenfeld M, Ratjen F. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study. Ann Am Thorac Soc. 2025 Nov; 22(11):1696-1708.
-
Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study. Am J Respir Crit Care Med. 2025 10; 211(10):1901-1914.
-
Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Waltz D, Ahluwalia N, Chu C, Scirica CV, Davies JC. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children =6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. Am J Respir Crit Care Med. 2025 Oct; 211(10):1915-1925.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|